Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-10-15 |
Forward Pharma (Denmark) |
$235.2 million |
IPO |
|
Autoimmune diseases - Neurodegenerative diseases |
IPO |
2014-10-15 |
TC BioPharm (UK) |
£100,000 (€125733) |
grant |
Scottish Enterprise (UK) |
Cancer - Oncology |
Grant |
2014-10-15 |
Atara Biotherapeutics (USA - CA) |
$ 55 millio |
IPO |
|
Cancer - Oncology - Kidney diseases - Renal diseases |
IPO |
2014-10-08 |
Mimetas (The Netherlands) |
$ 5.2 million (€4.1 million) |
fundraising |
Zeeuws Investerings Fonds (ZIF) (The Netherlands), Participatiemaatschapij Oost Nederland (PPM Oost) (The Netherlands), national and regional partners |
Technology - Services |
Fundraising |
2014-10-08 |
PTC Therapeutics (USA - NJ) |
|
IPO |
|
|
IPO |
2014-10-07 |
Atopix Therapeutics (UK) |
£1.7 million (€1.98 million) + £3.7 million (€4.32 million) |
grant - series A financing round |
Biomedical Catalyst Fund (UK) - MPM Capital - SV Life Sciences (UK- USA) - Wellington Partners (USA) - Bessemer Partners (USA) - Red Abbey (UK) - SR One (UK) |
Allergic diseases - Dermatological diseases |
Series A financing round |
2014-10-06 |
VBL Therapeutics (Israel) |
$34.4 million (€ 27.5 million) |
IPO |
|
Cancer - Oncology - Immunological diseases - Inflammatory diseases |
IPO |
2014-09-30 |
Vitamfero (France) |
€2.7 million |
capital increase |
Go Capital (France), Pradeyrol Développement (France), Business Angels affiliated with Val de France Angels (France) CapDecisif Management (France), G1J Ile-de-France (France), individual investors |
Infectious diseases |
Capital increase |
2014-09-29 |
Molmed (Italy) |
|
capital increase |
Société Générale (France) |
|
Capital increase |
2014-09-29 |
Nanovi (Denmark) |
€2.7 million |
fundraising |
Vækstfonden (Denmark) 3Shape A/S (Denmark) |
Cancer - Oncology |
Fundraising |
2014-09-25 |
Adaptimmune (UK) |
$104 million (€81.4 million) |
series A financing round |
New Enterprise Associates (NEA) (USA - MD) OrbiMed Advisors (USA - NY) Wellington Management Company, LLP (USA - MA), Fidelity Biosciences (USA - MA), Foresite Capital Management (USA - CA), Ridgeback Capital Management (USA - TX), Novo A/S (Denmark), QVT (USA - NY), Rock Springs Capital (USA - MD), venBio Select (USA - CA), Merlin Nexus (USA - NY), University of Oxford (UK) |
Cancer - Oncology |
Series A financing round |
2014-09-25 |
Videregen (UK) |
£1.2 million (€1.53 million) |
fundraising |
SPARK Impact (UK) London Business Angels (UK) and other investors |
Transplantation |
Fundraising |
2014-09-25 |
Santen Holdings (The Netherlands) |
€ 42 million (Approximately ¥6 billion) |
capital increase |
Santen Pharmaceutical (Japan) |
Ophtalmological diseases |
Capital increase |
2014-09-24 |
Evotec (Germany) |
€5 million |
grant |
German Ministry of Education and Research (BMBF) (Germany) |
Neurodegenerative diseases |
Grant |
2014-09-23 |
ProQR Therapeutics (The Netherlands) |
$102 million (€79.3 million) |
IPO |
|
|
IPO |
2014-09-23 |
nLife Therapeutics (Spain) |
$350,000 (€ 271,000) |
grant |
The Michael J. Fox Foundation - MJFF (USA) |
Neurodegenerative diseases |
Grant |
2014-09-23 |
BerGenBio (Norway) |
£1.6 million (NOK 16 million - € 2 million) |
convertible loan |
Wellcome Trust (UK) |
Cancer - Oncology |
Loan |
2014-09-23 |
Foamix Pharmaceuticals (Israel - USA - NJ) |
$35.7 million |
IPO |
|
|
IPO |
2014-09-22 |
Silarus Therapeutics (USA - CA) |
$ 10 million |
series A financing round |
GSK (UK) Avalon Venture (USA - CA) |
Metabolic diseases |
Series A financing round |
2014-09-22 |
Thyritope Biosciences (USA - CA) |
$ 10 million |
series A financing round |
GSK (UK) Avalon Venture (USA - CA) |
Autoimmune diseases |
Series A financing round |